Express Scripts (NSDQ:ESRX) said yesterday that it would include Mylan‘s (NSDQ:MYL) EpiPen emergency allergy device on its 2018 formulary, favoring the drugmaker’s product over auto-injectors from competitors like Impax Laboratories (NSDQ:IPXL) and Kaleo.
The largest pharmacy benefit manager in the U.S. has practiced excluding certain medicines from its list of covered drugs since 2014, pointing towards the high prices taken on by health insurers.
Get the full story at our sister site, Drug Delivery Business News.
The post Express Scripts covers Mylan’s EpiPen on 2018 formulary, excluding rivals appeared first on MassDevice.
from MassDevice http://ift.tt/2vjReUH
Cap comentari:
Publica un comentari a l'entrada